Due to its strong association with tumor progression, selective targeting of SphK1 is emerging as a promising strategy in cancer therapy [19], and, recently, inhibition of SphK1 using selective agents, such as PF-543, has demonstrated promising cytotoxic effects in preclinical models by disrupting S1P signaling and sensitizing cancer cells to conventional therapies [19,21,22]. This evidence concerns the gene MBTPS1 and cancer.